Eagle Pharmaceuticals Inc is an established pharmaceutical company that upholds core values of innovation, integrity, and patient-centered approach. Committed to providing high-quality solutions, Eagle Pharmaceuticals Inc aims to improve patient outcomes by developing and commercializing injectable products. The company focuses on enhancing existing drugs through patent-protected modifications, promoting efficacy and safety. Eagle Pharmaceuticals Inc is dedicated to developing products that address unmet medical needs and offer value to both healthcare professionals and patients. With a strong emphasis on research and development, Eagle Pharmaceuticals Inc strives to make a positive impact on the pharmaceutical industry and improve the lives of individuals through its innovative offerings.

Eagle Pharmaceuticals Inc primarily operates in the United States and focuses on the development and commercialization of injectable products. The company's presence is primarily centered in North America.

Eagle Pharmaceuticals Inc has achieved significant milestones, positioning itself as a key player in the pharmaceutical industry. The company successfully developed innovative and improved formulations of existing drugs, such as Ryanodex® and BENDEKA®. These formulations received FDA approvals, demonstrating the company's commitment to delivering better treatment options for patients. Eagle Pharmaceuticals Inc also achieved multiple partnerships and collaborations, expanding its portfolio and global reach. The company's dedication to research and development has paved the way for future advancements in healthcare. As a result, Eagle Pharmaceuticals Inc continues to enhance its presence in the market, offering innovative solutions that address critical medical needs.

Eagle Pharmaceuticals Inc, a renowned pharmaceutical company, has a rich history and background. Established in 2007, the company is headquartered in Woodcliff Lake, New Jersey. Eagle Pharmaceuticals focuses on developing and commercializing innovative injectable drugs. With a strong emphasis on novel formulations and techniques, they aim to enhance patient care and expand treatment options. The company's dedication to research and development has resulted in multiple FDA-approved medications, addressing critical medical needs. Eagle Pharmaceuticals Inc continues to thrive in the pharmaceutical industry, leveraging its expertise and commitment to delivering high-quality therapies for patients worldwide.

The main competitors of Eagle Pharmaceuticals Inc in the market are Sandoz Inc, Fresenius Kabi USA LLC, and Akorn Inc.

Eagle Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Eagle Pharmaceuticals Inc revolves around the development and commercialization of injectable products in the healthcare sector. Eagle Pharmaceuticals focuses on creating novel formulations of existing FDA-approved drugs, thereby improving therapeutic options and patient outcomes. Through strategic partnerships and collaborations, the company aims to enhance its product portfolio and expand its market reach. By leveraging its expertise and innovative technologies, Eagle Pharmaceuticals Inc strives to provide safe, effective, and cost-efficient solutions for various medical conditions. The company's commitment to research and development, alongside its strong industry presence, positions it as a trusted player in the pharmaceutical market.

مُعامل القيمة السوقية إلى الأرباح لـ Eagle Pharmaceuticals هو ١٫٢٤.

مُعامِل القيمة إلى المبيعات Eagle Pharmaceuticals هو ٠٫٢٥.

نقاط جودة AlleAktien لـ Eagle Pharmaceuticals هي 7/10.

المتوقعة Eagle Pharmaceuticals الإيرادات هي ٢١٥٫٧٣ مليون. USD.

صافي الربح المتوقعة Eagle Pharmaceuticals هو ٤٣٫٣٣ مليون. USD.

The business model of Eagle Pharmaceuticals is focused on developing and commercializing specialized pharmaceutical products and therapies for the treatment of serious diseases. The company offers a wide range of products for various medical conditions, including treatments for bleeding and malignant hyperthermia. They also engage in licensing agreements with other companies to generate revenue from their intellectual property. Eagle Pharmaceuticals utilizes a differentiated marketing strategy, collaborates closely with healthcare professionals, and invests heavily in research and development to achieve a strong presence in the market.

يوزع Eagle Pharmaceuticals أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Eagle Pharmaceuticals في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـEagle Pharmaceuticals هو US2697961082.

رمز WKN لـ Eagle Pharmaceuticals هو A1XEDS.

الرمز المُختصر لـ Eagle Pharmaceuticals هو EGRX.

خلال آخر 12 شهراً، دفعت Eagle Pharmaceuticals توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Eagle Pharmaceuticals خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Eagle Pharmaceuticals هي .

Eagle Pharmaceuticals يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Eagle Pharmaceuticals دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Eagle Pharmaceuticals يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Eagle Pharmaceuticals المُعلن عنها في ١٢‏/٨‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١٢‏/٨‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١٢‏/٨‏/٢٠٢٤.

في العام 2023، وزعت Eagle Pharmaceuticals 0 USD كأرباح أسهم.

يتم توزيع أرباح Eagle Pharmaceuticals بالعملة USD.